Biosimilars are biologic medicines that are highly similar to existing licensed biologic products with no clinically meaningful differences in the terms of safety and efficacy.
However, the process of introducing a biosimilar to an innovator product is far more complex than the relatively straightforward process of introducing a generic equivalent to an innovator product based on a new chemical entity. Biosimilars are being developed by an abbreviated route of development, that can help to have cost effective & more access to the potential patients. With $67 billion in global sales of biologic medicines anticipated to go off patent by 2020, even modest reductions in the cost of biosimilars products could have a meaningful impact on health care systems around the world. For physicians and their patients, biosimilars provide additional therapeutic options.
For more details, download White Paper here:
Data integrity for supply chain operations, Powered by blockchain technology